Other
Myelosuppression:SIKLOS may cause severe myelosuppression. Monitor blood counts at baseline and throughout treatment. Interrupt treatment and reduce dose as necessary [see Warnings and Precautions (5.1)] .
Malignancies:Hydroxyurea is carcinogenic. Advise sun protection and monitor patients for malignancies [see Warnings and Precautions (5.2)] .
Administration:
The tablets should be taken once daily, at the same time each day, with a glass of water. For patients who are not able to swallow the tablets, these can be dispersed immediately before usein a small quantity of water in a teaspoon.
SIKLOS is a cytotoxic drug. Follow applicable special handling and disposal procedures [see References (15)].
Tablets:
- 100 mg tablets: off-white, capsule-shaped, film-coated, functionally scored tablet with scoring on both sides which can be divided into two equal parts, each part is debossed with "H" on one side.
- 1,000 mg tablets: off-white, capsule-shaped, film-coated, functionally triple-scored tablet with scoring on both sides which can be divided into four equal parts, each part is debossed with "T" on one side.
Pancreatitis
Pancreatitis (including fatal cases) have occurred in patients with HIV infection during therapy with hydroxyurea and didanosine, with or without stavudine. Hydroxyurea is not indicated for the treatment of HIV infection; however, if patients with HIV infection are treated with hydroxyurea, and in particular, in combination with didanosine and/or stavudine, monitor closely for signs and symptoms of pancreatitis. Permanently discontinue therapy with hydroxyurea in patients who develop signs and symptoms of pancreatitis.
Hepatotoxicity
Hepatotoxicity and hepatic failure resulting in death have been reported during postmarketing surveillance in patients with HIV infection treated with hydroxyurea and other antiretroviral drugs. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. Avoid this combination.
Peripheral Neuropathy
Peripheral neuropathy, which was severe in some cases, has been reported in patients with HIV infection receiving hydroxyurea in combination with antiretroviral drugs, including didanosine, with or without stavudine.
Interference with Uric Acid, Urea, or Lactic Acid Assays
Studies have shown that there is an analytical interference of SIKLOS with the enzymes (urease, uricase, and lactate dehydrogenase) used in the determination of urea, uric acid, and lactic acid, rendering falsely elevated results of these in patients treated with SIKLOS.
Interference with Continuous Glucose Monitoring Systems
Hydroxyurea may falsely elevate sensor glucose results from certain continuous glucose monitoring (CGM) systems and may lead to hypoglycemia if sensor glucose results are relied upon to dose insulin.
If a patient using a CGM is to be prescribed hydroxyurea, consult with the CGM prescriber about alternative glucose monitoring methods.
Risk Summary
SIKLOS can cause fetal harm based on findings from animal studies and the drug's mechanism of action [see Clinical Pharmacology (12.1)] . There are no studies with the use of SIKLOS in pregnant women, and limited available data on SIKLOS use during pregnancy are insufficient to inform drug-associated risks. Drugs which affect DNA synthesis, such as hydroxyurea, may be potential mutagenic agents. In animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m 2basis. In rats and rabbits, fetal malformations were observed with partially ossified cranial bones, absence of eye sockets, hydrocephaly, bipartite sternebrae, and missing lumbar vertebrae. Embryotoxicity was characterized by decreased fetal viability, reduced live litter sizes, and developmental delays (see Data) . Advise pregnant women of the potential risk to a fetus (see Clinical Considerations).
Background risk of major birth defects and miscarriage for the indicated population are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively.
Clinical Considerations
Fetal/Neonatal adverse reactions
Although the data on a limited number of exposed pregnancies indicate no adverse effects on pregnancy or on the health of the fetus/newborn, patients on SIKLOS should be made aware of the potential risks to the fetus.
Based on the limited amount of available information, in case of an exposure to SIKLOS of pregnant female patients or pregnant partners of male patients, treated by SIKLOS, a careful follow-up with adequate clinical, biological and ultrasonographic examinations should be considered.
Data
Human Data
According to a retrospective analysis of a cohort of 123 adult patients treated with hydroxyurea, twenty-three pregnancies have been reported from 15 women treated with hydroxyurea and partners of 3 men not using barrier contraception treated with hydroxyurea. Most (61%) had no adverse developmental outcomes. In the other cases with known evolution, pregnancy had been interrupted either voluntarily or upon medical advice.
In retrospective cohorts of 352 children and adolescents with sickle cell disease older than 2 years treated with hydroxyurea for a period of up to 12 years, 3 pregnancies under hydroxyurea were reported with no adverse developmental outcomes.
From post-marketing data of SIKLOS, 3 pregnancies have been reported while the father was treated with SIKLOS and 16 pregnancies have been reported in 15 females treated with SIKLOS. Among the 13 cases with known evolution, 5 pregnancies had no adverse developmental outcomes, 4 led to premature birth, and 4 were early terminated.
Animal Data
Hydroxyurea has been demonstrated to be a potent teratogen in a wide variety of animal models, including mice, hamsters, cats, miniature swine, dogs, and monkeys at doses within 1-fold of the human dose given on a mg/m 2basis. Hydroxyurea is embryotoxic and causes fetal malformations (partially ossified cranial bones, absence of eye sockets, hydrocephaly, bipartite sternebrae, missing lumbar vertebrae) at 180 mg/kg/day (about 0.8 times the maximum recommended human daily dose on a mg/m 2basis) in rats and at 30 mg/kg/day (about 0.3 times the maximum recommended human daily dose on a mg/m 2basis) in rabbits. Embryotoxicity was characterized by decreased fetal viability, reduced live litter sizes, and developmental delays. Hydroxyurea crosses the placenta. Single doses of ≥375 mg/kg (about 1.7 times the maximum recommended human daily dose on a mg/m 2basis) to rats caused growth retardation and impaired learning ability.
Risk Summary
It is not known whether SIKLOS is excreted in human milk, the effects of SIKLOS on the breastfed child, or the effects of SIKLOS on milk production. Because of the potential for serious adverse reactions in a breastfed child from SIKLOS, including carcinogenicity, advise patients not to breastfeed during treatment with SIKLOS.
Pregnancy Testing
SIKLOS can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)] .
Verify the pregnancy status of females of reproductive potential prior to initiating SIKLOS therapy.
Contraception
Females
Advise females of reproductive potential to use effective contraception during and after treatment with SIKLOS for at least 6 months after therapy. Advise females to immediately report pregnancy.
Males
SIKLOS may damage spermatozoa and testicular tissue, resulting in possible genetic abnormalities. Males with female sexual partners of reproductive potential should use effective contraception during and after treatment with SIKLOS for at least 6 months after therapy [see Nonclinical Toxicology (13.1)] .
Infertility
Males
Based on findings in animals and humans, male fertility may be compromised by treatment with SIKLOS. Azoospermia or oligospermia, sometimes reversible, has been observed in men. Before the start of therapy, inform male patients about the possibility of sperm conservation [see Adverse Reactions (6)and Nonclinical Toxicology (13.1)] .
Absorption
Following oral administration, hydroxyurea reaches peak plasma concentrations in 1 to 4 hours. The oral bioavailability of hydroxyurea was reported to be 85 -100%.
Effect of Food
There are no data on the effect of food on the absorption of hydroxyurea.
Distribution
Hydroxyurea distributes throughout the body with a volume of distribution approximating total body water. Hydroxyurea concentrates in leukocytes and erythrocytes.
Elimination
Half-life of hydroxyurea is about 2-4 hours.
Metabolism
Up to 60% of an oral dose undergoes conversion through saturable hepatic metabolism and a minor pathway of degradation by urease found in intestinal bacteria.
Excretion
The percentage of the dose excreted in urine was approximately 40% in pediatric patients with sickle cell anemia.
Specific Populations
Patients with Renal Impairment
The effect of renal impairment on the pharmacokinetics of hydroxyurea was assessed in adult patients with sickle cell anemia and renal impairment. Patients with normal renal function (creatinine clearance [CrCl] >80 mL/min), mild (CrCl 50-80 mL/min), moderate (CrCl =30-<50 mL/min), or severe (<30 mL/min) renal impairment received a single oral dose of 15 mg/kg hydroxyurea. Creatinine clearance values were obtained using 24-hour urine collections. Patients with ESRD received two doses of 15 mg/kg separated by 7 days; the first was given following a 4-hour hemodialysis session, the second prior to hemodialysis. The exposure to hydroxyurea (mean AUC) in patients with CrCl <60 mL/min and those with ESRD was 64% higher than in patients with normal renal function (CrCl >60 mL/min). Reduce the dose of SIKLOS when it is administered to patients with creatinine clearance of <60 mL/min or with ESRD following hemodialysis [see Dosage and Administration (2.2)and Use in Specific Populations (8.6)].
Patients with Hepatic impairment
There are no data that support specific guidance for dose adjustment in patients with hepatic impairment.
Pediatric Patients
The pharmacokinetics of hydroxyurea is similar between children (4 to 17 years) and adults.
Pediatric Patients with Sickle Cell Disease
The efficacy of SIKLOS was assessed in the European Sickle Cell Disease Cohort study (ESCORT HU) [NCT02516579]. This is an open-label single-arm study of 405 pediatric patients with sickle cell disease from 2-18 years of age, of which 141 had not been previously treated with hydroxyurea prior to enrollment. Evaluable patients had at least 12 months follow-up (median [range] 23 months [12,80]). Median (range) hemoglobin F percentages were 5.6% (1.3, 15.0) at baseline and 12.8% (2.1, 37.2) at least 6 months (the value closest to 6 months collected between 5 and 14 months) after initiation of SIKLOS treatment, with median (range) change of 5.9% (-2.2, 34.7) in 47 patients. Median (range) hemoglobin levels were 8.2 g/dL (3.7, 14.2) at baseline, 8.8 g/dL (0.7, 13.1) at 6 months (the value closest to 6 months collected between 5 and 7 months), and 8.9 g/dL (5.5, 13.2) at 12 months (the value closest to 12 months collected between 10 and 14 months) after initiation of SIKLOS treatment. The median (range) change was 0.5 g/dL (-4.6, 6.1) in 63 patients at 6 months (the post-baseline value closest to 6 months collected between 5 and 7 months) and 0.7 g/dL (-6.4, 6.0) in 83 patients at 12 months (the post-baseline value closest to 12 months collected between 10 and 14 months) after initiation of SIKLOS treatment.
Among pediatric patients not previously treated with hydroxyurea prior to enrollment and analyzable for efficacy (N=141), the percentage of patients with at least one vaso-occlusive episode, one episode of acute chest syndrome, one hospitalization due to SCD or one blood transfusion decreased after 12 months of SIKLOS treatment (Table 4).
| SCD events | Patients under 18 years old previously not treated with hydroxyurea with at least 12 months follow-up data available for clinical efficacy (N=141) | ||
|---|---|---|---|
| In the 12 months prior to enrolment | After 12 months of Siklos ®treatment | Change | |
| Number of patients with at least one vaso-occlusive episode (in 120 evaluable patients) | |||
| No | 37 (31%) | 69 (57.5%) | |
| Yes | 83 (69%) | 51 (42.5%) | |
| Number of vasoocclusive episodes over 12 months (in 113 evaluable patients) | |||
| Median (range) | 2 (0, 1) | 0 (0.0, 7.0) | -1 (-10.0, 5.0) |
| Number of patients with at least one episode of acute chest syndrome (in 123 evaluable patients) | |||
| No | 94 (76%) | 116 (94%) | |
| Yes | 29 (24%) | 7 (6%) | |
| Number of episodes of acute chest syndrome over 12 months (in 123 evaluable patients) | |||
| Median (range) | 0 (0.0, 2.0) | 0 (0.0, 1.0) | 0 (-2.0, 1.0) |
| Number of patients with at least one hospitalization related to SCD (in 110 evaluable patients) | |||
| No | 27 (25%) | 64 (58%) | |
| Yes | 83 (75%) | 46 (42%) | |
| Number of hospitalizations related to SCD over 12 months (in 106 evaluable patients) | |||
| Median (range) | 2 (0.0, 6.0) | 0 (0.0, 7.0) | -1 (-6.0, 6.0) |
| Number of days of hospitalizations related to SCD over 12 months (in 100 evaluable patients) | |||
| Median (range) | 8 (0.0, 58.0) | 0 (0.0, 100.0) | -3 (-58.0, 86.0) |
| Number of patients with at least one blood transfusion (in 122 evaluable patients) | |||
| No | 66 (54%) | 94 (77%) | |
| Yes | 56 (46%) | 28 (23%) | |
Adult Patients with Sickle Cell Disease
In ESCORT-HU 1077 adult patients were included of which 436 patients were naïve to HU treatment. There were 370 evaluable patients who had at least 12 months follow-up (Median [range] 41 months [29, 54].
Median (range) hemoglobin F percentages were 5.2% (0.2, 30.9) at baseline and 14.2% (0.5, 41.5) at least 6 months (the value closest to 6 months collected between 5 and 14 months) after initiation of SIKLOS treatment, with a median (range) change of 8% (-8.0, 33.3) in 181 patients. Among adult patients previously not treated with hydroxyurea prior to enrollment and analyzable for efficacy (N=370), the incidence and number of vaso-occlusive events, hospitalizations, acute chest syndrome and blood transfusions in the 12 month period before treatment and after initiation of treatment decreased after 12 months of SIKLOS treatment. Table 5 provides the efficacy results for ESCORT-HU.
| SCD events | Adult Patients previously not treated with hydroxyurea with at least 12 months follow-up data available for clinical efficacy (N=369) | ||
|---|---|---|---|
| In the 12 months prior to enrolment | After 12 months of Siklos ®treatment | Change | |
| Number of patients with at least one vaso-occlusive episode (in 367 evaluable patients) | |||
| No | 133 (36.2%) | 226 (61.6%) | |
| Yes | 234 (63.8%) | 141 (38.4%) | |
| Number of vasoocclusive episodes over 12 months (in 343 evaluable patients) | |||
| Median (range) | 1.0 (0.0, 20.0) | 0.0 (0.0, 30.0) | 0.0 (-20.0, 24.0) |
| Number of patients with at least one episode of acute chest syndrome (in 365 evaluable patients) | |||
| No | 273 (74.8%) | 338 (92.6%) | |
| Yes | 92 (25.2%) | 27 (7.4%) | |
| Number of episodes of acute chest syndrome over 12 months (in 364 evaluable patients) | |||
| Median (range) | 1.0 (0.0, 5.0) | 0.0 (0.0, 3.0) | 0.0 (-5.0 ; 2.0) |
| Number of patients with at least one hospitalization related to SCD (in 366 evaluable patients) | |||
| No | 152 (41.5%) | 252 (68.9%) | |
| Yes | 214 (58.5%) | 114 (31.1%) | |
| Number of hospitalizations related to SCD over 12 months (in 360 evaluable patients) | |||
| Median (range) | 1 (0.0, 15.0) | 0 (0.0, 10.0) | 0 (-15.0, 8.0) |
| Number of days of hospitalizations related to SCD over 12 months (in 313 evaluable patients) | |||
| Median (range) | 2 (0.0, 90.0) | 0 (0.0, 77.0) | 0 (-90.0, 57.0) |
| Number of patients with at least one blood transfusion (in 365 evaluable patients) | |||
| No | 207 (56.7%) | 296 (81.1%) | |
| Yes | 158 (43.3%) | 69 (18.9%) | |
Distributed by:
Medunik USA, 2 Research Way, suite 1B, Princeton, NJ 08540.
Manufactured for. Theravia: 16 rue Montrosier 92200 Neuilly-sur-Seine France
Manufactured by: Delpharm Lille, 22 rue de Toufflers 59452 Lys Lez Lannoy France
SIKLOS is a trademark of Theravia.